Citius Pharmaceuticals (CTXR) Stock Price, Financials & Analysis

Key Stats

Market Cap10.37 Mn

P/E-0.22

P/S1.46

Div. Yield0.00

Total Debt (Qtr)6.41 Mn

Add ratio to table…

About

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first in class critical care products focusing on oncology anti infectives in adjunct cancer care and unique prescription products. The company aims to secure leading market positions by offering therapies that address unmet medical needs while carrying lower development risk than typical new chemical entities. Its strategy centers on products protected by…

Revenue currently comes from sales of the FDA approved lymphoma therapy LYMPHIR which was launched by the company's majority owned subsidiary Citius Oncology in December 2025. Additional revenue is anticipated from late stage candidates including Mino Lok a catheter lock solution for bloodstream infections Halo Lido a topical hemorrhoid treatment and Nove Cite a mesenchymal stem cell therapy for acute respiratory distress syndrome. The company may also earn milestone payments and royalties from licensing and partnership arrangements.

In the oncology space LYMPHIR competes with approved agents such as Mogamulizumab (Poteligeo) Brentuximab vedotin (Adcetris) Romidepsin (Istodax) and Vorinostat (Zolinza) for cutaneous T cell lymphoma. Its competitive advantage lies in a unique mechanism that delivers diphtheria toxin to IL 2 expressing cells while depleting regulatory T cells and in its orphan drug status and patent protection. For catheter infection Mino Lok offers a salvage alternative to the standard practice of removing and replacing contaminated central venous catheters facing competition mainly from procedural risks rather than approved drugs. Halo Lido seeks to become the first FDA approved prescription product for hemorrhoids a market currently dominated by over the counter options. Nove Cite targets acute respiratory distress syndrome where it differentiates itself from donor derived mesenchymal stem cell therapies through higher potency scalable production and consistent quality.

The company serves hospitals oncology clinics dermatology practices and hemodialysis centers. Specific distribution partners include Cardinal Health Cencora McKesson Corporation EVERSANA and Integris Pharma S. A. which support the commercialization of LYMPHIR in various regions.

How Citius Pharmaceuticals ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.24xMedian 16.8x 9^th
P/FCFNegative free cash flow −0.33xMedian 18.3x 9^th
P/Operating cash flowNegative operating cash flow −0.33xMedian 17.0x 9^th
P/S 1.62xMedian 9.38x 84^th
P/B 0.15xMedian 2.17x 95^th
P/Tangible book 0.15xMedian 2.42x 95^th
EV/EBITDA —Median 15.7x No data —
EV/EBITNegative EBIT −0.02xMedian 19.8x 1^st
EV/Revenue 0.13xMedian 6.59x 99^th
EV/FCFNegative free cash flow −0.03xMedian 19.2x 1^st
EV/Operating cash flowNegative operating cash flow −0.03xMedian 16.0x 1^st
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 10.2% No data —
Revenue CAGR (3Y) —Median 10.2% No data —
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −49.2%Median 0.0% 21^st
Operating income CAGR (3Y) −21.6%Median 1.6% 24^th
Net income growth (1Y) −38.2%Median −5.1% 32^nd
Net income CAGR (3Y) −23.9%Median −0.4% 25^th
EPS growth (1Y) 52.5%Median 21.0% 69^th
EPS CAGR (3Y) −107%Median 25.3% 4^th
Operating cash flow growth (1Y) −69.5%Median 0.3% 15^th
Operating cash flow CAGR (3Y) −6.9%Median 2.4% 37^th
Free cash flow growth (1Y) −69.5%Median 0.3% 15^th
Free cash flow CAGR (3Y) −6.9%Median 3.3% 37^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.0% No data —
EBITDA margin —Median −216% No data —
Operating margin −864%Median −230% 33^rd
Pretax margin −816%Median −223% 33^rd
Net margin −651%Median −230% 35^th
FCF margin −491%Median −168% 36^th
Operating cash flow margin −491%Median −157% 36^th
Return on equity −80.2%Median −53.5% 37^th
Return on assets −42.3%Median −42.0% 49^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −71.6%Median −46.0% 34^th
Asset turnover 0.05xMedian 0.18x 33^rd
Cash conversion (OCF / net income)Net income is not positive 0.60xMedian 1.21x Not meaningful —
Stock comp / revenue 208%Median 27.5% 23^rd

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 4.5%Median 20.0% 80^th
Debt / equity 0.08xMedian 0.26x 74^th
Net debt / EBITDA —Median 1.82x No data —
Debt / FCFFree cash flow is not positive −0.18xMedian 3.03x Not meaningful —
Liabilities / assets 46.6%Median 32.8% 40^th
Equity / assets 53.4%Median 67.2% 40^th
Interest coverage −119xMedian −10.1x 19^th
Current ratio 0.84xMedian 4.48x 12^th
Quick ratio 0.34xMedian 3.72x 9^th
Cash ratio 0.33xMedian 3.34x 13^th
Altman Z-score −4.07Median −0.62 34^th

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.4% No dividend —
Net buyback yieldAbove 100% of market value −441%Median −3.3% Not meaningful —
Shareholder yieldAbove 100% of market value −441%Median −2.3% Not meaningful —
Payout ratio (earnings) —Median 50.9% No dividend —
Payout ratio (FCF) —Median 45.2% No dividend —
Dividend growth (1Y) —Median 3.9% No dividend —
Dividend CAGR (3Y) —Median 3.5% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,136.97 Bn	42.57	14.27	54.91 Bn
2	JNJ	Johnson & Johnson	619.72 Bn	29.46	6.33	49.04 Bn
3	ABBV	AbbVie Inc.	503.40 Bn	79.78	7.82	70.82 Bn
4	MRK	Merck & Co., Inc.	370.15 Bn	116.66	5.56	53.91 Bn
5	NVS	Novartis Ag	298.64 Bn	18.93	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.07 Bn	24.99	4.45	32.35 Bn
7	AMGN	Amgen Inc	237.00 Bn	27.11	6.22	57.30 Bn
8	CTXR	Citius Pharmaceuticals, Inc.	0.01 Bn	-0.22	1.46	0.01 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,136.97 Bn

42.57

14.27

54.91 Bn

JNJ

Johnson & Johnson

619.72 Bn

29.46

6.33

49.04 Bn

ABBV

AbbVie Inc.

503.40 Bn

79.78

7.82

70.82 Bn

MRK

Merck & Co., Inc.

370.15 Bn

116.66

5.56

53.91 Bn

NVS

Novartis Ag

298.64 Bn

18.93

5.45

9.59 Bn

AZN

Astrazeneca Plc

261.07 Bn

24.99

4.45

32.35 Bn

AMGN

Amgen Inc

237.00 Bn

27.11

6.22

57.30 Bn

CTXR

Citius Pharmaceuticals, Inc.

0.01 Bn

-0.22

1.46

0.01 Bn

Citius Pharmaceuticals CTXR

About

How Citius Pharmaceuticals ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Citius Pharmaceuticals CTXR

About

How Citius Pharmaceuticals ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password